International Journal of Medical and All Body Health Research  |  e-ISSN: 2582-8940  |  Double-Blind Peer Review  |  Open Access  |  CC BY-NC-SA 4.0

Current Issues
     2026:7/4

International Journal of Medical and All Body Health Research

e-ISSN: 2582-8940 | Open Access

Treatment and vaccination of Covid-19

Muhammad Akram, Tehreem Riaz, Isha Ishtiaq, Husnain Karim Riaz, Sana Shahzadi, Marriyam Talat, Saba Irfan, Wasfa Farooq, Sara Khan

Department of Eastern Medicine, Government College University Faisalabad Pakistan; Department of Biotechnology, University of Sialkot, Pakistan; Department of Microbiology, University of Central Punjab, Pakistan

Article Information

Volume / Issue1 / 2 (April-June 2020)
Pages01-07
AccessOpen Access

Publication Timeline

  • Received25 February 2020
  • Accepted10 March 2020

Full Text (PDF)

Open Access - Free to Download

Download Full Article (PDF) JATS XML

Abstract

The outbreak of this wide-ranging pandemic has forced the world to identify and produce the therapeutics for the treatment & prevention of it. The Covid-19 is a virulent pneumonia-like disease caused by SARS-COV-2. This pandemic has caused several thousands of deaths. For a few months this pandemic has set pressure on laborites to diagnose this novel virus properly and on the pharmacists, researchers, doctors, scientists, and pharmaceutical companies to develop proper medicine and vaccination against this virus. Proper diagnosis and treatment are essential to treat patients suffering from covid-19. Despite extraordinary advancements in the medical field, presently, there is no effective treatment for this global pandemic. However, fast and rapid research on the epidemiology of SARS-COv-2 is helping in unveiling the potential therapeutic against covid-19.clinical trials and screening for drug development are going on some drugs. Favipiravir, Remdesivir, & dexamethasone have shown promising potential against covid-19. Interferon, tocilizumab, and convalescent plasma therapy have beneficial effects on viral clearance. Trials are going also going on viral S protein targeting vaccines. This review aims to summarize all current therapeutic advancements and vaccinations in the global medicinal system against covid-19.

Keywords

Covid-19clinical featuresdiagnosistreatment of covid-19anti-viralsteroidsantibioticsvaccination

References

  1. Alhazzani W, Møller M, Arabi Y, Loeb M, Gong M, Fan E, Du B. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive care medicine, 2020, 1-34. [Google Scholar][Crossref]
  2. Belyakov IM, Ahlers JD. What role does the route of immunization play in the generation of protective immunity against mucosal pathogens? The Journal of Immunology. 2009; 183(11):6883-6892. [Google Scholar][Crossref]
  3. Biot C, Daher W, Chavain N, Fandeur T, Khalife J, Dive D, De Clercq E. Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities. Journal of medicinal chemistry. 2006; 49(9):2845-2849. [Google Scholar][Crossref]
  4. Bonow R, Fonarow G, O’Gara P, Yancy C. Association of Coronavirus Disease 2019 (COVID-19) With Myocardial Injury and Mortality JAMA Cardiol. Published online March, 2020, 27. [Google Scholar][Crossref]
  5. Buchholz UJ, Bukreyev A, Yang L, Lamirande EW, Murphy BR, Subbarao K, et al. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proceedings of the National Academy of Sciences. 2004; 101(26):9804-9809. [Google Scholar][Crossref]
  6. Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020; 105932:(10.1016). [Google Scholar][Crossref]
  7. Commission, N. H. (2020). Diagnosis and treatment protocol for novel coronavirus pneumonia (Trial Version 7). Chin Med J (Engl), 133(9), 1087-1095. [Google Scholar][Crossref]
  8. Cortegiani, A., Ingoglia, G., Ippolito, M., Giarratano, A., & Einav, S. (2020). A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. Journal of critical care. [Google Scholar][Crossref]
  9. CS, S., & Madathilkovilakathu, H. (2020). Drug repurposing for COVID-19 from FDA approved and experiment stage drugs by in silico methods with SARS CoV-2 spike protein. [Google Scholar][Crossref]
  10. Delang, L., Abdelnabi, R., & Neyts, J. (2018). Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral research, 153, 85-94. [Google Scholar][Crossref]
  11. Gautret, P., Lagier, J.-C., Parola, P., Meddeb, L., Mailhe, M., Doudier, B., . . . Dupont, H. T. (2020). Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International journal of antimicrobial agents, 105949. [Google Scholar][Crossref]
  12. Hui, D. S., Azhar, E. I., Madani, T. A., Ntoumi, F., Kock, R., Dar, O., . . . Drosten, C. (2020). The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—The latest 2019 novel coronavirus outbreak in Wuhan, China. International Journal of Infectious Diseases, 91, 264-266. [Google Scholar][Crossref]
  13. Khalid, N., Chen, Y., Case, B. C., Shlofmitz, E., Wermers, J. P., Rogers, T., . . . Waksman, R. (2020). COVID-19 (SARS-Cov-2) and the heart–An ominous association. Cardiovascular Revascularization Medicine. [Google Scholar][Crossref]
  14. Leng, Z., Zhu, R., Hou, W., Feng, Y., Yang, Y., Han, Q., . . . Wang, S. (2020). Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging and disease, 11(2), 216. [Google Scholar][Crossref]
  15. Liu, Y., Li, J., & Feng, Y. (2020). Critical care response to a hospital outbreak of the 2019-nCoV infection in Shenzhen, China: BioMed Central. [Google Scholar][Crossref]
  16. Matzneller, P., Krasniqi, S., Kinzig, M., Sörgel, F., Hüttner, S., Lackner, E., . . . Zeitlinger, M. (2013). Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy. Antimicrobial agents and chemotherapy, 57(4), 1736-1742. [Google Scholar][Crossref]
  17. Organization, W. H. (2014). Use of convalescent whole International Journal of Medical and all body Health Research http://www.allmedicaljournal.com 7 blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks: interim guidance for national health authorities and blood transfusion services: World Health Organization. [Google Scholar][Crossref]
  18. Park, S.-Y., Kim, J.-H., Kim, H.-J., Seo, B., Kwon, O. Y., Chang, H. S., . . . Park, C.-S. (2018). High prevalence of asthma in elderly women: findings from a Korean national health database and adult asthma cohort. Allergy, asthma & immunology research, 10(4), 387-396. [Google Scholar][Crossref]
  19. Ratia, K., Pegan, S., Takayama, J., Sleeman, K., Coughlin, M., Baliji, S., . . . Johnson, M. E. (2008). A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. Proceedings of the National Academy of Sciences, 105(42), 16119-16124. [Google Scholar][Crossref]
  20. Rauch, S., Jasny, E., Schmidt, K. E., & Petsch, B. (2018). New vaccine technologies to combat outbreak situations. Frontiers in immunology, 9, 1963. [Google Scholar][Crossref]
  21. Roden, D. M., Harrington, R. A., Poppas, A., & Russo, A. M. (2020). Considerations for drug interactions on QTc in exploratory COVID-19 (coronavirus disease 2019) treatment. Circulation. [Google Scholar][Crossref]
  22. Savarino, A., Di Trani, L., Donatelli, I., Cauda, R., & Cassone, A. (2006). New insights into the antiviral effects of chloroquine. The Lancet infectious diseases, 6(2), 67-69. [Google Scholar][Crossref]
  23. Scagnolari, C., Vicenzi, E., Bellomi, F., Stillitano, M. G., Pinna, D., Poli, G., . . . Antonelli, G. (2004). Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons. Antivir Ther, 9(6), 1003-1011. [Google Scholar][Crossref]
  24. Sheahan, T. P., Sims, A. C., Leist, S. R., Schäfer, A., Won, J., Brown, A. J., . . . Clarke, M. O. (2020). Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. nature COMMUNICATIONS, 11(1), 1-14. [Google Scholar][Crossref]
  25. Shen, C., Wang, Z., Zhao, F., Yang, Y., Li, J., Yuan, J., . . . Xing, L. (2020). Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA, 323(16), 1582-1589. [Google Scholar][Crossref]
  26. Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., . . . Xiao, G. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell research, 30(3), 269-271. [Google Scholar][Crossref]
  27. Xing, Z., Afkhami, S., Bavananthasivam, J., Fritz, D. K., D'Agostino, M. R., Vaseghi‐Shanjani, M., . . . Jeyanathan, M. (2020). Innate immune memory of tissue‐resident macrophages and trained innate immunity: Re‐vamping vaccine concept and strategies. Journal of leukocyte biology. [Google Scholar][Crossref]
  28. Yang, X., Yu, Y., Xu, J., Shu, H., Liu, H., Wu, Y., . . . Yu, T. (2020). Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet Respiratory Medicine. [Google Scholar][Crossref]
  29. Yao, Y., Jeyanathan, M., Haddadi, S., Barra, N. G., Vaseghi-Shanjani, M., Damjanovic, D., . . . Dvorkin-Gheva, A. (2018). Induction of autonomous memory alveolar macrophages requires T cell help and is critical to trained immunity. Cell, 175(6), 1634-1650. e1617. [Google Scholar][Crossref]
  30. Saeed, U., Uppal, S. R., Piracha, Z. Z., Khan, A. A., Rasheed, A., Waheed, A., ... & Uppal, R. (2021). Evaluation of SARS-CoV-2 spike antibody levels among Sputnik V first dose vaccinated people in Pakistan: formulation of national anti-COVID-19 mass vaccination strategy. [Google Scholar][Crossref]
  31. Khurana, A., Allawadhi, P., Khurana, I., Allwadhi, S., Weiskirchen, R., Banothu, A. K., ... & Bharani, K. K. (2021). Role of nanotechnology behind the success of mRNA vaccines for COVID-19. Nano Today, 38, 101142. [Google Scholar][Crossref]

How to Cite

Akram, M., Riaz, T., Ishtiaq, I., Riaz, H. K., Shahzadi, S., Talat, M., Irfan, S., Farooq, W., & Khan, S. (2020). Treatment and vaccination of Covid-19. International Journal of Medical and All Body Health Research, 1(2), 01-07.

Akram, Muhammad, et al. "Treatment and vaccination of Covid-19." International Journal of Medical and All Body Health Research, vol. 1, no. 2, 2020, pp. 01-07.

Akram, M., Riaz, T., Ishtiaq, I., Riaz, H. K., Shahzadi, S., Talat, M., Irfan, S., Farooq, W. and Khan, S. (2020) 'Treatment and vaccination of Covid-19', International Journal of Medical and All Body Health Research, 1(2), pp. 01-07.

Akram M, Riaz T, Ishtiaq I, Riaz HK, Shahzadi S, Talat M, et al. Treatment and vaccination of Covid-19. International Journal of Medical and All Body Health Research. 2020;1(2):01-07.

Similar Articles

Share

Find this Article on

Google Scholar Semantic Scholar OpenAlex ResearchGate BASE

A newly published article may take a few days to appear on these services.